Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
TC Biopharm (Holdings) Plc focuses on developing cell therapy products for cancer treatment, with a primary emphasis on its lead product, TCB-001, targeting hematological malignancies. The company operates primarily in the UK and Europe, leveraging its proprietary technology platform to create innovative therapies that aim to enhance patient outcomes.
TC Biopharm's business model is centered around the development and commercialization of advanced cell therapies. The company aims to monetize its innovations through product sales, partnerships, and licensing agreements, although it currently lacks revenue generation. Its competitive advantage lies in its proprietary technology and focus on unmet medical needs in oncology.
Clinical trial results for TCB-001, particularly Phase II outcomes
Regulatory approvals from the FDA or EMA
Partnership announcements with larger pharmaceutical companies
Funding rounds or grants that enhance liquidity
Regulatory changes that could impact the approval process for new therapies
Technological disruption from competing cell therapy innovations
Emergence of alternative therapies that may outperform TCB-001
Increased competition from established biotech firms with more resources
High cash burn rate leading to potential liquidity issues
Limited revenue generation creating reliance on external funding
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare services remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates could increase the cost of capital for funding R&D and clinical trials, potentially impacting the company's ability to finance its operations.
minimal - The company has a manageable debt-to-equity ratio of 0.67, indicating limited reliance on external credit.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, with a 1-year return of -77.8%.
